Dimitris Skokos, M.Sc., PhD, joined Regeneron in 2008 as Staff Scientist and now serves as Vice President of Cancer Immunology. Dimitris' team is responsible for developing the next generation of combination immunotherapeutic strategies including the costimulatory bispecific antibodies and other foundational antibody medicines to treat cancer. He holds more than 10 patents and 30 publications and was part of the team that developed the FDA approved treatment for metastatic cutaneous squamous cell carcinoma, Basal Cell Carcinoma and advanced Non-Small Cell Lung Cancer, Libtayo. He has had the honor to work with esteem scientists, George D. Yancopoulos and Roy P. Vagelos. Prior to joining Regeneron, Dr Skokos was a post-doctoral fellow at the Rockefeller University, working with Ralph Steinman (Nobel Laureate, 2011) and Michel Nussenzweig. He received his PhD in Molecular Immunology from the Pasteur Institute, University Paris 5, Rene Descartes School of Medicine, and his BSc. in Cellular Immunology and Physiology from University Paris, France.